Rodríguez Ángel, Parra Guillermo, Cuervas-Mons Manuel
Department of Orthopaedics and Trauma Surgery, 'Gregorio Marañón' General University Hospital, Madrid, Spain.
Department of Orthopaedics and Trauma Surgery, 'Gregorio Marañón' General University Hospital, Madrid, Spain.
Foot (Edinb). 2021 Sep;48:101831. doi: 10.1016/j.foot.2021.101831. Epub 2021 May 25.
The bioactive glass (BAG) is a promising solution for the reconstruction of bone defects and the eradication of infection in patients with osteomyelitis, however references to the treatment of diabetic foot osteomyelitis are scarce in the literature.
Our experience in patients with diabetic foot osteomyelitis, who required surgical debridement and void filling, in which we use bioactive glass (n = 6), was evaluated. During a minimum follow-up of 24 months, the presence of persistent infection and healing rate, post-surgical complications, surgical reinterventions, degree of osseointegration and BAG-related side effects was analyzed.
At the end of the follow-up, none of the patients showed signs of persistent infection and the healing rate was 66.6% (4/6). Postoperative complications were noted in 3 patients and two of the them required new surgical intervention, both due to skin coverage or vascular complications. A complete osseointegration in the 66.6% of the patients and no cases of local adverse effects were recorded.
The bioactive glass can be a useful tool in the treatment of certain cases of diabetic foot osteomyelitis, provided that a multidisciplinary approach and strict patient selection is in place.
IV.
生物活性玻璃(BAG)是修复骨缺损和根除骨髓炎患者感染的一种有前景的解决方案,然而,文献中关于糖尿病足骨髓炎治疗的参考资料很少。
我们评估了6例需要手术清创和骨缺损填充的糖尿病足骨髓炎患者使用生物活性玻璃的经验。在至少24个月的随访期间,分析了持续感染的存在情况、愈合率、术后并发症、再次手术干预、骨整合程度以及与生物活性玻璃相关的副作用。
随访结束时,所有患者均无持续感染迹象,愈合率为66.6%(4/6)。3例患者出现术后并发症,其中2例因皮肤覆盖或血管并发症需要再次手术干预。66.6%的患者实现了完全骨整合,未记录到局部不良反应病例。
如果采取多学科方法并严格选择患者,生物活性玻璃可以成为治疗某些糖尿病足骨髓炎病例的有用工具。
IV级